 | Clinical Guidelines Resources |
Back to Resource Center Main
 |
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
The American College of Cardiology/American Heart Association Task Force on Practice Guidelines, is charged with the mission to develop and revise practice guidelines for important cardiovascular diseases and procedures. This site offers healthcare providers help with making clinical decisions by describing a range of generally acceptable approaches for the diagnosis, management, or prevention of Chronic Heart Failure in the adult.
|
|
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
The purpose of JNC reports is to synthesize the
available scientific evidence and offer guidance
to busy primary care clinicians. This site offers an evidence-based approach to the prevention and management of
hypertension.
|
|
Clinical Guidelines on Cholesterol Management in Adults (ATP III)
The Third Report of the Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol
in Adults (Adult Treatment Panel III, or ATP III)
presents the National Cholesterol Education Program’s
(NCEP’s) updated recommendations for cholesterol
testing and management.
|
|
AHA: Recommendations Regarding Public Screening for Measuring Blood Cholesterol
National Cholesterol Education Program (NCEP)is a consortium of practitioners, public health professionals, voluntary health organizations, and government agencies, who participate in a collaborative effort of professional and public education. Here they present updated guidelines on how to lower cholesterol levels in the general population.
|
|
National Guideline Clearinghouse: ACC/AHA 2006 guidelines for the management of patients with valvular heart disease
American College of Cardiology/American Heart Association Task Force on Practice Guidelines presents here guidelines to assist physicians in clinical decision making by describing a range of generally acceptable approaches for management of valvular heart disease. As well as to improve the effectiveness of care, optimize patient outcomes, and favorably affect the overall cost of care by focusing resources on the most effective strategies
|
|
Antithrombotic Therapy for Venous Thromboembolic Disease: The SeventhACCP Conference on Antithrombotic and Thrombolytic Therapy
These recommendations on the antithrombotic therapy for
venous thromboembolic diseases are part of the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Recommendations are divided into two categories: Grade 1 recommendations are strong and
indicate that the benefits do, or do not, outweigh
risks, burden, and costs and Grade 2 suggests that
individual patients’ values may lead to different
choices
|
|
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: The SeventhACCP Conference on Antithrombotic and Thrombolytic Therapy
These recommendations about treatment and prevention of
stroke are a part of the 7th ACCP Conference on Antithrombotic
and Thrombolytic Therapy: Evidence Based Guidelines. The recommendations are in two categories: Grade 1 recommendations are strong and indicate that the benefits do, or do not,
outweigh risks, burden, and costs and Grade 2 suggests
that individual patients’ values may lead to different
choices.
|
|
AHA Scientific Statement: Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women
The recommendations presented are designed to assist healthcare providers in optimizing CVD preventive care for all women age 20 years and older. Implementation of these guidelines may differ among countries and regions for cultural, medical, and economic reasons. In addition, application of these guidelines should also take into consideration individual factors such as frailty and life expectancy
|
|
Use of Nonsteroidal Antiinflammatory Drugs: A Scientific Statement From the American Heart Association
These guidelines were created in response to clinical trial data which has prompted questions about the degree to which patients and their physicians should consider an increased risk of cardiovascular or cerebrovascular events when selecting medications for pain relief. It provides clinicians with a stepwise approach to treating chronic pain and inflammation.
|
|
|
